ALFA Filings
Every announcement, straight from the exchange
Every Torrent Pharmaceuticals earnings call announcement on NSE and BSE, newest first, each with its own page.
Time
4 announcements with these filters
Revenue grew 51% following the JB Chemicals merger, but underlying business shows integration headwinds.
Torrent Pharma delivered strong Q1 performance with revenues up 55% following the JB Chemicals merger completion. EBITDA margins jumped to 33.8% driven by accelerated cost synergies.
Torrent Pharma Q4 FY26 revenue rose 42% to ₹4,197cr, driven by JB Pharma consolidation. Combined EBITDA margin stood at 32.3%, with focus on Semaglutide ramp-up in India and synergy execution.
Torrent Pharma delivered strong Q4 growth led by India and Brazil, while successfully integrating Curatio and JB Pharma assets.